How is Farydak used in multiple myeloma?
In the United States, Farydak® (panobinostat, Novartis) is approved by the Food and Drug Administration (FDA) in combination with Velcade® (bortezomib, Takeda Oncology) and dexamethasone. It is used for patients who have already received at least two other treatments, including Velcade and an immunomodulatory agent (IMiD®, such as Revlimid® [lenalidomide, Celgene], Thalomid® [thalidomide, Celgene], or Pomalyst® [pomalidomide, Celgene]), and whose disease has progressed (gotten worse) on their last therapy.
What types of patients can benefit from Farydak therapy?
Farydak has been shown to be effective in patients with relapsed and refractory myeloma following treatment with other available agents, including those who have received a stem cell transplant. In the trial supporting the FDA approval of Farydak, 59% of patients who did not respond to or could not tolerate Velcade and an IMiD responded to the combination of Farydak, Velcade, and dexamethasone. Farydak was also shown to have activity in patients with high-risk disease.
How does Farydak work?
Farydak is a histone deacetylase inhibitor. It inhibits multiple enzymes that cancer cells need to grow and survive. Farydak appears to act synergistically with other anti-myeloma drugs, that is, combining the drugs is more effective than either one alone. Farydak also inhibits the growth of new blood vessels needed for tumors to grow.